



Financial Tear Sheet

Corporate Profile

Founded in 2006, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is focused on the development, commercialization, and manufacturing of innovative ocular therapies using its HYDROME(TM) technology. Our product pipeline candidates utilize our platform to provide differentiated drug delivery solutions that are designed to greatly reduce the complexity and burden of current drop of injection regimens by creating sustained release, one-time or several-month dosage forms. The sustained release of these drugs can be tailored to produce the expected efficacy with a potentially improved safety profile, since they are used in lower peak concentrations and in the case of topical medications, are preservative-free. It is our intention to develop a product portfolio that will overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing, simplifying the burdensome and complex regimens of current therapies.

Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. The company's first commercial product, the ReSure® Sealant, is the first and only sealant that has been approved by the Food and Drug Administration (FDA) for ophthalmic use.

Stock Performance

OCUL (Common Stock)

Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	\$5.84
Change (%)	▲ 0.04 (0.69%)
Volume	82,164
52 Week Low	\$4.83
Market Cap	\$168,530,432
Rolling EPS	-2.12
PE Ratio	0
Shares Outstanding	29,056,971

Data as of 08/17/17 4:00 p.m. ET



Recent Headlines & Events

08/08/17 - 4:05 p.m.

[Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update](#)

08/03/17 - 4:06 p.m.

[Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality](#)

08/01/17 - 4:05 p.m.

[Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/08/17	4
08/08/17	10-Q
08/08/17	8-K
08/03/17	3

Corporate Governance

Amarpreet Sawhney, Ph.D.	President, Chief Executive Officer and Chairman of the Board of Directors
Jim Fortune	Chief Operating Officer
Peter Jarrett, Ph.D.	Chief Technical Officer
Jonathan Talamo, M.D.	Chief Medical Officer
Eric Ankerud, J.D.	Executive Vice President, Clinical, Regulatory and Quality
Scott Corning	Vice President, Sales and Marketing
Art Driscoll	Vice President, Product Development

Data provided by Nasdaq. Minimum 15 minutes delayed.